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Background:  The  National  Toxicology  Program  (NTP)  performed  short-term  toxicity  studies  of  tetra-
and  pentavalent  vanadium  compounds,  vanadyl  sulfate  and  sodium  metavanadate,  respectively.  Due
to widespread  human  exposure  and  a lack  of  chronic  toxicity  data,  there  is concern  for human  health
following  oral  exposure  to  soluble  vanadium  compounds.
Objectives:  To  compare  the  potency  and  toxicological  proﬁle  of  vanadyl  sulfate  and  sodium  metavanadate
using  a  short-term  in  vivo toxicity  assay.
Methods:  Adult  male  and  female  Harlan  Sprague  Dawley  (HSD)  rats  and  B6C3F1/N  mice, 5  per  group,  were
exposed  to  vanadyl  sulfate  or sodium  metavanadate,  via  drinking  water,  at concentrations  of  0,  125, 250,
500,  1000  or  2000  mg/L  for 14  days.  Water consumption,  body  weights  and  clinical  observations  were
recorded  throughout  the study;  organ  weights  were  collected  at study  termination.
Results: Lower  water  consumption,  up  to −80% at 2000  mg/L,  was  observed  at  most  exposure  concen-
trations  for  animals  exposed  to either  vanadyl  sulfate  or sodium  metavanadate  and  was  accompanied
by  decreased  body  weights  at the  highest  concentrations  for both  compounds.  Animals  in  the  1000  and
2000  mg/L  sodium  metavanadate  groups  were  removed  early  due  to  overt  toxicity.  Thinness  was  observed
in high-dose  animals  exposed  to either  compound,  while  lethargy  and  abnormal  gait were  only  observed
in  vanadate-exposed  animals.
Conclusions:  Based  on clinical  observations  and overt  toxicity,  sodium  metavanadate  appears  to  be  more
toxic  than  vanadyl  sulfate.  Differential  toxicity  cannot  be explained  by differences  in  total  vanadium
intake,  based  on  water  consumption,  and  may  be  due  to  differences  in disposition  or mechanism  of
toxicity.
© 2016  The  Author(s).  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
Vanadium is a naturally occurring metal, found in several miner-
ls and fossil fuels and exists in various oxidation states from −1 to
5 [5]. It has been estimated that natural processes, such as volcanic
ruptions and weathering, result in the release of 65k tons of vana-
ium into the environment, while anthropogenic sources add an
dditional 200k tons per year [30]. Anthropogenic sources of vana-
ium include various industrial processes, e.g. coal-ﬁred power
lant production of ﬂy ash and intermediates of iron smelting. In
∗ Corresponding author at: National Institute of Environmental Health Sciences,
.O. Box 12233, Mail Drop: K2-07, Research Triangle Park, NC, 27709, United States.
E-mail address: hooth@niehs.nih.gov (M.J. Hooth).
ttp://dx.doi.org/10.1016/j.toxrep.2016.05.001
214-7500/© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open acces
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
addition to domestic generation of vanadium-containing industrial
waste, the United States imports additional waste and intermedi-
ates for use in steel production; in 2013 it was reported that more
than 9000 t of vanadium (as ferrovanadium, vanadium pentoxide
or ash and residues) were imported by the U.S. [22]. Likely due to its
industrial uses, vanadium has been detected at several Superfund
sites (at least 319 out of 1699) as classiﬁed by the EPA [2].
The National Toxicology Program (NTP) has previously stud-
ied the carcinogenic potential of vanadium pentoxide in male
and female F344/N rats and B6C3F1/N mice following chronic
whole-body inhalation exposure, up to 2 mg/m3. Exposure to vana-
dium pentoxide is primarily occupational. Chronic exposure to
vanadium pentoxide resulted in increased incidences of several
non-neoplastic lesions of the respiratory tract (lung, larynx, nose)
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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nd increased incidences of alveolar/bronchiolar neoplasms in
ale and female mice, and to some degree in male rats [16]. Vana-
ium pentoxide has since been listed on California’s Proposition 65
ist of chemicals “Known to the State [of California] to Cause Cancer
r Reproductive Toxicity” and classiﬁed as “Possibly Carcinogenic
o Humans”, category 2B, by the International Agency for Research
n Cancer [9,20].
While occupational exposure to vanadium primarily occurs via
nhalation, environmental exposure occurs largely via ingestion of
oluble vanadium compounds. Ingestion of vanadium may  include
ietary supplements, food or contaminated drinking water. Due to
eing a ubiquitous element, food is considered the primary source
f exposure to vanadium. Many foods naturally contain some vana-
ium, with the amounts varying based on soil/water conditions and
he extent of vanadium absorption into the food product. Back-
round consumption of vanadium from food is estimated to be
etween 10 and 60 g daily [2,15]. Anthropogenic sources of vana-
ium have the potential to increase human exposure to vanadium
hrough food and drinking water. Vanadium (V) levels in soil from
on-contaminated areas range from 3 to 310 g V/g soil and have
een measured up to 400 g V/g soil in ﬂy ash contaminated areas
30]. Fly ash contamination of drinking water may  also contribute to
anadium exposure; in North Carolina, the Department of Environ-
ental and Natural Resources (NC DENR) has led efforts to assess
anadium drinking water contamination due to ﬂy ash leakage. The
oal Ash Management Act of 2014 enforced by the NC DENR has
equired Duke Energy to test any well within 1500 feet of all Duke
nergy coal-ﬁred facilities in the state. Data released in August 2015
ist vanadium as an analyte exceeding the N.C. interim maximum
llowable concentration (0.3 g/L) at 10 of the 11 sites, with 2–118
ells tested at each site [19]. In addition, vanadium has been stud-
ed by numerous investigators due to reported effects on glucose
etabolism; a summary of the therapeutic history of vanadium
nd diabetes can be found in [28]. Outside of potential pharmaceu-
ics, vanadium is also sold as a dietary supplement with purported
eneﬁts including cholesterol metabolism and enhancing athletic
erformance.
Due to industrial releases of vanadium into the environment
nd consumption of dietary supplements, there is concern for
uman health following chronic oral exposure to soluble vanadium
alts. The uncertainty regarding safety of vanadium consump-
ion is further complicated by the existence of multiple oxidation
tates with the potential to interconvert via oxidation-reduction,
oth in the environment and following ingestion. Highly oxidized
orms of vanadium, +3 to +5, are considered the most stable forms
nd are most likely to be found as environmental contaminants;
anadyl sulfate, a tetravalent form (VIV), is one of the dietary sup-
lements advertised for diabetes and cholesterol. Studies in the
iterature suggest that oral exposure to vanadium (VIV or VV) may
ave immunological, neurological, reproductive/developmental
nd general toxicity effects [12,6,7,11,21,24,25]. Despite the
umerous studies published on vanadium compounds, the avail-
ble literature lacks an adequate comparison of VIV and VV, under
 standard study design, in two rodent species exposed in drinking
ater, the most relevant route of exposure.
Vanadium has gained recognition on the federal level by being
ncluded in the U.S. Environmental Protection Agency’s (U.S. EPA)
raft drinking water Contaminant Candidate List 4, or CCL4, which
ill be ﬁnalized in 2016 [29]. Tetravalent and pentavalent vana-
ium compounds were nominated to the NTP for testing, in part by
he U.S. EPA, and the critical data gaps have been outlined by the
gency for Toxic Substances and Disease Registry [2]. Some data
aps highlighted by ATSDR include comprehensive subchronic and
hronic toxicity testing, with an adequate comparison of different
xidation states under similar testing conditions. To help address
ncertainties regarding the safety of oral exposure to vanadium,eports 3 (2016) 531–538
the NTP conducted 14-day drinking water studies of vanadyl sul-
fate (VIV) and sodium metavanadate (VV) in adult Harlan Sprague
Dawley rats and B6C3F1/N mice at exposure concentrations of
0, 125, 250, 500, 1000 or 2000 mg/L. These exposure concentra-
tions were selected based on a critical review of the literature and
consideration of the following: palatability, adult versus perinatal
toxicity, the relative toxicity of pentavalent versus tetravalent com-
pounds and an overall lack of toxicity data in mice. Vanadyl sulfate
was selected as the VIV test article due to its use in dietary sup-
plements. Sodium metavanadate was selected as a representative
VV species following characterization of drinking water formula-
tions of sodium orthovanadate and sodium metavanadate [13]. The
designs of the two studies were essentially identical to facilitate
comparisons between the two  valence states. These data will help
inform the design and exposure concentration selection for sub-
chronic and chronic toxicity assessments of vanadium, which will
provide essential data for the risk assessment of vanadium follow-
ing oral exposure.
2. Methods
2.1. Chemical and dose formulation
Vanadyl sulfate (CASRN 27774-13-6, Lot No.0210324/1.1) was
purchased from Noah Technologies Corporation (San Antonio, TX).
Sodium metavanadate (CASRN 13718-26-8, Lot No. 8579K) was
purchased from MP  Biomedicals (Santa Ana, CA). The identity
of each vanadium compound was  determined by infrared spec-
troscopy, X-ray diffraction, and proton-induced X-ray emission
spectroscopy. The overall purity, determined by high performance
liquid chromatography (HPLC) with charged aerosol detection,
was 100 and 99.5% for vanadyl sulfate and sodium metavanadate,
respectively.
Drinking water formulations (0, 125, 250, 500, 1000, 2000 mg/L)
of sodium metavanadate (∼pH 7) and vanadyl sulfate (∼pH 3.5)
were prepared using tap water from the City of Columbus, Ohio
municipal supply. Formulations were analyzed with HPLC with
ultraviolet detection prior to study start and following the last
exposure; all samples were within ±10% of the target concentra-
tion and 0 mg/L formulations were below the limit of quantitation
of the analytical method (vanadyl sulfate 0.43 mg/L, sodium meta-
vanadate 0.46 mg/L).
The stability of formulations was  established prior to study start.
Sodium metavanadate and vanadyl sulfate formulations were sta-
ble for up to 42 days; at day 42, sodium metavanadate was 99–101%
of day 0 and vanadyl sulfate was 92–100% of day 0 when stored pro-
tected from light at ∼5 ◦C or room temperature. In some vanadyl
sulfate formulations, a small peak was observed ≥day 7, in the HPLC
chromatogram at the retention time of vanadate, suggesting slight
oxidation of vanadyl to vanadate [13].
2.2. Animals and animal maintenance
The studies presented here were conducted at Battelle Memo-
rial Institute (West Jefferson, OH). Harlan Sprague Dawley (HSD)
rats were purchased from Harlan (Indianapolis, IN). B6C3F1/N mice
were supplied from the NTP colony at Taconic Biosciences (Ger-
mantown, NY). Upon arrival, animals were quarantined for at least
10 days and provided ad libitum access to irradiated NTP-2000
wafer feed (Zeigler Brothers, Inc., Gardeners, PA) and tap water.
Following quarantine, 5–7 week-old animals were randomized into
exposure groups by body weight. Animals were uniquely identiﬁed
by tail tattoo upon randomization. On study day one, animals were
placed on control or dosed-water (125, 250, 500, 1000, 2000 mg/L)
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Table  1
Clinical observations in (A) Harlan Sprague Dawley rats and (B) B6C3F1/N mice: sodium metavanadate or vanadyl sulfate.
(A)
mg/L Sodium Metavanadate Vanadyl Sulfate
♂ ♀ ♂ ♀
0 None None None None
125  None None None None
250  None None None None
500  None None None • Thin (4/5)
1000  • Thin (3/5) • Thin (3/5) None • Thin (5/5)
•  Rufﬂed coat (2/5)
• Hunched posture (2/5)
• Shallow breathing (1/5)
•  Lethargic (2/5) • Lethargic (2/5)
•  Abnormal gait (2/5)
•  Discharge
Eye, brown (3/5)
Nose, red (1/5)
2000 • Thin (5/5) • Thin (4/5) • Thin (5/5) • Thin (5/5)
•  Rufﬂed coat (3/5) • Rufﬂed coat (5/5)
•  Hunched posture (2/5) • Hunched posture (1/5) • Hunched posture (2/5)
•  Shallow breathing (1/5)
•  Lethargic (0/5) • Lethargic (1/5)
•  Abnormal gait (3/5) • Abnormal gait (2/5)
•  Discharge • Discharge
Eye, brown (1/5) Nose, red (1/5)
Nose, red (1/5)
(B)
mg/L Sodium Metavanadate Vanadyl Sulfate
♂ ♀ ♂ ♀
0 None None None None
125  None None None None
250  None None None None
500  • Thin (2/5) • Thin (2/5) None None
•  Rufﬂed coat (1/5) • Rufﬂed coat (2/5)
• Hunched posture (1/5) • Hunched posture (2/5)
•  Shallow breathing (1/5)
• Rapid Breathing (1/5)
•  Lethargic (1/5)
• Abnormal gait (1/5) • Abnormal gait (2/5)
1000 • Thin (4/5) • Thin (5/5) • Thin (2/5) • Thin (5/5)
•  Rufﬂed coat (5/5) • Rufﬂed coat (5/5)
• Hunched posture (5/5) • Hunched posture (4/5)
•  Shallow breathing (4/5) • Shallow breathing (1/5)
•  Rapid breathing (1/5)
•  Lethargic (5/5)
• Abnormal gait (5/5) • Abnormal gait (5/5)
2000 • Thin (1/5) • Thin (5/5) • Thin (5/5) • Thin (5/5)
•  Rufﬂed coat (5/5) • Rufﬂed coat (4/5) • Rufﬂed coat (3/5) • Rufﬂed coat (1/5)
•  Hunched posture (5/5) • Hunched posture (5/5) • Hunched posture (3/5)
•  Shallow breathing (1/5)
 (2/5)
5/5)
a
a
v
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W• Rapid Breathing
•  Lethargic (1/5)
• Abnormal gait (5/5) • Abnormal gait (
d libitum. Rats and female mice were housed 5 animals per cage
nd male mice were individually housed.
Animal use was in accordance with the U.S. Public Health Ser-
ice policy on humane care and use of laboratory animals and the
uide for the Care and Use of Laboratory Animals [14]. Animals were
reated humanely and with regard for alleviation of suffering. These
tudies were conducted in compliance with the Food and Drug
dministration Good Laboratory Practice Regulation [8].
.3. Study designGroups of 5 male and 5 female HSD rats and B6C3F1/N mice
ere exposed to vanadyl sulfate or sodium metavanadate at con-
entrations of 0, 125, 250, 500, 1000 or 2000 mg/L for 2 weeks.
ater consumption was  measured twice weekly. Animals exposedto sodium metavanadate at concentrations of 1000 and 2000 mg/L
were removed from the study by day 9; therefore, values in
Tables 2A and B and 3 represent the average for the ﬁrst week only
for those groups. Animals were observed for mortality and morbid-
ity twice daily. Body weights were recorded prior to study start and
twice weekly thereafter. All animals were euthanized humanely
by CO2 inhalation and subjected to complete necropsies and gross
examination of tissues. Organ weights for the liver, thymus, kid-
neys, testes, epididymides, ovaries, heart and lungs were recorded;
all bilateral organs were weighed separately.2.4. Statistical methods
Body weights, organ weights and water consumption were ana-
lyzed for treatment related effects by the Jonchkeere trend test.
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Table 2A
Water consumption (g/day)in Harlan Sprague Dawley rats: sodium metavanadate
or  vanadyl sulfate.
mg/L Sodium Metavanadate Vanadyl Sulfate
♂ ♀ ♂ ♀
0 22.0 17.0 27.9 18.0
125  21.0 (−4.5) 17.0 (0.0) 22.1 (−20.8)** 17.2 (−4.4)**
250 18.8 (−14.5) 14.2 (−16.5) 21.3 (−23.7)** 16.3 (−9.4)**
500 14.9 (−32.3) 11.7 (−31.2) 18.6 (−33.3)** 14.4 (−20.0)**
1000 6.5 (−70.5) 7.2 (−57.6) 14.6 (−47.7)** 10.1 (−43.9)**
2000 3.6 (−83.6) 2.3 (−86.5) 6.0 (−78.5)** 4.1 (−77.2)**
Values represent group averages (percent difference from 0 mg/L group). No stan-
dard error is presented because the animals were group housed 5 animals/cage and 5
animals/group. Averages for vanadyl sulfate and 0–500 mg/L sodium metavanadate
are  for study days 1–15. The averages presented for 1000 and 2000 mg/L sodium
metavanadate are for study days 1–8, due to early removal.
** Indicates statistical signiﬁcance, p-value ≤ 0.01.
Table 2B
Water consumption (g/day) in B6C3F1/N mice: sodium metavanadate or vanadyl
sulfate.
mg/L Sodium Metavanadate Vanadyl Sulfate
♂ ♀ ♂ ♀
0 3.4 ± 0.1 2.0 3.4 ± 0.2 2.5
125  3.3 ± 0.1 (−2.9) 2.2 (10.0) 3.3 ± 0.0 (−2.9) 2.1 (−16.0)**
250 3.7 ± 0.6 (1.1) 1.9 (−5.0) 3.3 ± 0.1 (−2.9) 1.7 (−32.0)**
500 2.4 ± 0.2 (−29.4)** 1.2 (−40.0) 2.5 ± 0.1 (−26.5)** 1.4 (−44.0)**
1000 1.1 ± 0.1 (−67.6)** 0.7 (−65.0) 1.8 ± 0.1 (−47.1)** 0.9 (−64.0)**
2000 1.0 ± 0.1 (−70.6)** 0.3 (−85.0) 1.1 ± 0.1 (−67.6)** 0.5 (−80.0)**
Values represent group averages ± SEM (percent difference from 0 mg/L group).
Standard error is only presented for male mice; female mice were group housed
5  animals/cage with 5 animals/group while male mice were singly housed. Aver-
ages for vanadyl sulfate and 0–500 mg/L sodium metavanadate are for study days
1–15. The averages presented for 1000 and 2000 mg/L sodium metavanadate are for
study days 1–8, due to early removal.
** Indicates statistical signiﬁcance, p-value ≤ 0.01.
Table 3
Chemical consumption (mg/kd/day)in (A) Harlan Sprague Dawley rats and (B)
B6C3F1/N mice: sodium metavanadate or vanadyl sulfate.
(A)
mg/L Sodium Metavanadate Vanadyl Sulfate
♂ ♀ ♂ ♀
0 0.00 0.00 0.00 0.00
125 12.9 (5.4) 14.5 (6.0) 13.1 (4.1) 15.2 (4.7)
250  24.1 (10.4) 25.3 (10.5) 26.0 (8.1) 29.1 (9.0)
500  39.1 (16.3) 42.5 (17.7) 46.2 (14.3) 51.7 (16.0)
1000 43.4 (18.1) 59.6 (24.8) 76.2 (23.6) 75.6 (23.5)
2000 48.2 (20.1) 43.8 (18.3) 77.5 (24.0) 80.1 (24.8)
(B)
mg/L Sodium Metavanadate Vanadyl Sulfate
♂ ♀ ♂ ♀
0 0.00 0.00 0.00 0.00
125 18.4 (7.7) 15.3 (6.4) 17.4 (5.4) 14.9 (4.6)
250  41.1 (17.1) 26.5 (11.0) 34.6 (10.7) 25.3 (7.8)
500  58.2 (24.3) 38.5 (16.1) 53.1 (16.5) 42.4 (13.1)
1000 60.3 (25.1) 48.8 (20.3) 81.3 (25.2) 60.7 (18.8)
2000 112.5 (46.9) 46.7 (19.5) 115.2 (35.7) 83.6 (25.9)
Values represent group averages for compound consumption and (total vana-
dium). Vanadium consumption was calculated from water consumption/chemical34 G.K. Roberts et al. / Toxico
airwise comparisons were done using either the Shirley or Dunn
ests for water consumption and the Williams or Dunnett tests for
ody and organ weights.
. Results
.1. Survival and clinical observations
Exposure to vanadyl sulfate had no impact on survival in male or
emale, HSD rats or B6C3F1/N mice. Male rats exposed to vanadyl
ulfate exhibited thinness in the 2000 mg/L exposure group only,
hile female rats exhibited thinness at lower exposure concen-
rations and hunched posture at 2000 mg/L (Table 1A). No clinical
bservations were noted in male rats below 2000 mg/L or female
ats below 1000 mg/L. Clinical observations for mice exposed to
igh exposure concentrations of vanadyl sulfate included rufﬂed
oat, hunched posture and thinness (Table 1B). No clinical obser-
ations were noted for mice in the 125, 250 or 500 mg/L groups.
Decreased survival was observed in mice and rats exposed to
igh concentrations of sodium metavanadate. For rats, one male
nd one female in the 2000 mg/L group were found dead on days
 and 7, respectively. In mice, three males and one female in the
000 mg/L exposure group were found dead on days 7 and 8. No
eaths were observed in rats in the 1000 mg/L group or mice in
he 2000 mg/L groups, however, due to clinical observations, lower
ater consumption and mortality in other groups, the decision
as made to remove all remaining rats and mice in the 1000 and
000 mg/L groups by day 8. One male mouse in the 500 mg/L group
as found dead on day 8, however mortality/moribunidty was  not
een in other male mice in this group.
Additional clinical observations were noted in animals exposed
o sodium metavanadate compared to vanadyl sulfate. Rats
xposed to sodium metavanadate exhibited thinness, rufﬂed coat,
unched posture, shallow breathing, lethargy, abnormal gait and
ischarge from the eye (brown) and nose (red) (Table 1A). These
bservations were noted in male rats at 1000 or 2000 mg/L, while
emale rats only displayed most of these symptoms at the highest
xposure concentration. No clinical observations were noted in rats
xposed to less than 1000 mg/L sodium metavanadate.
Overall, mice, especially females, appeared to be more sensi-
ive to the effects of sodium metavanadate exposure compared
o rats, with most clinical observations being noted down to the
00 mg/L exposure group (Table 1B). Similar to the rats, mice exhib-
ted thinness, rufﬂed coat, hunched posture, shallow breathing,
apid breathing, lethargy and abnormal gait. Only one male mouse
n the 500 mg/L group, the animal found dead on day 8, exhibited
linical observations other than thinness. No clinical observations
ere noted in mice exposed to 125 or 250 mg/L sodium metavana-
ate.
.2. Water and chemical consumption
Lower water consumption, likely due to palatability, was
bserved for both compounds, at nearly all concentrations in
xposed animals. Animals in the 2000 mg/L exposure groups
vanadyl/vanadate, males/females, rats/mice) consumed between
7.6 and 86.5% less water than their concurrent controls
Table 2A and B ). Lower water consumption resulted in less
han proportional compound exposure, at concentrations greater
han 250 mg/L. Exposure to the compound and total vanadium,
ased on water consumption, is shown in Table 3A (rats) and B
mice). Vanadium comprises 31% of vanadyl sulfate and 41.7% of
odium metavanadate as a weight percentage; therefore, animals
xposed to sodium metavanadate consume more vanadium, per
ram of water, than animals exposed to vanadyl sulfate, at the same
consumption; vanadium comprises 31% of vanadyl sulfate and 41.7% of sodium
metavanadate. Averages for vanadyl sulfate and 0–500 mg/L sodium metavanadate
are for study days 1–15. The averages presented for 1000 and 2000 mg/L sodium
metavanadate are for study days 1–8, due to early removal.
G.K. Roberts et al. / Toxicology Reports 3 (2016) 531–538 535
0 5 10 15
100
150
200
250
300
aa
aabb
bb
cc
c
ccdd
d
0 5 10 15
100
150
200
aa
aa
bb
bb
c
c
0 5 10 15
12
15
18
21
24
27
aa
aabb
bb
cc
cc
cc
0 5 10 15
9
12
15
18
21
aa
aa
bb
bb
c
c c
0 5 10 15
100
150
200
250
300
aa
aa
aa
aa 
bb
bb
b
0 5 10 15
100
150
200
aa
aa
aa
aa
bb
0 5 10 15
15
18
21
24
27
aa
aa aa
aa
bb
bb
b
bb
0 5 10 15
9
12
15
18
21
aa aa
aa
aa
bb bbb
bb
Sodium Metavanadate Vanadyl Sulfat e
M
al
e 
R
at
s
M
al
e 
M
ic
e
Fe
m
al
e 
R
at
s
Fe
m
al
e 
M
ic
e
0 5 10 15
0
0
0
0
0
Stud y Da y
B
od
y 
W
ei
gh
t (
g)
 
Study Day 
Legend: 
A B 
C D 
E F 
G H 
0 mg/L
125 mg/L
250 mg/L
500 mg/L
1000 mg/L
2000 mg/L
Fig. 1. Body Weight Curves. Body weight curves for animals exposed to sodium metavanadate are found in the left column and vanadyl sulfate in the right column, allowing
comparison between compounds within a given sex/species; males rats are the ﬁrst row (A, B), female rats the second row (C, D), male mice the third row (E, F) and female
mice  the fourth row (G, H). The x-axes represent study day and the y-axes are body weight in grams. Values shown are group averages, n = 4–5. Standard errors are not
shown to increase visibility of the curves; all standard errors were less than 10% and often less than 5%. Statistical signiﬁcance is shown for pair-wise tests against concurrent
c g/L vs
0  for 1
c 00 mg
e
p
montrols, single letter is p-value ≤ 0.05, double letter is p-value ≤ 0.01: ‘a’ for 2000 m
 mg/L. Legend: closed grey circles are used for 0 mg/L, closed black squares are used
losed grey diamonds are used for 1000 mg/L and open black circles are used for 20
xposure concentration. Due to early removal, consumption data
resented in Tables 2A and B and 3 for 1000 or 2000 mg/L sodium
etavanadate represent the average for study days 1–8 only.. 0/mg/L, ‘b’ for 1000 mg/L vs. 0 mg/L, ‘c’ for 500 mg/L vs. 0 mg/L, ‘d’ for 250 mg/L vs.
25 mg/L, x marks are used for 250 mg/L, open black triangles are used for 500 mg/L,
/L.
3.3. Body weightsLower body weights, compared to controls, and sometimes
decreases in body weight, were observed in both sex/species
exposed to either vanadyl sulfate or sodium metavanadate in the
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Table 4
Liver and kidney weights in male Harlan Sprague Dawley rats: sodium metavanadate
or  vanadyl sulfate.
mg/L Sodium
Metavanadate
Vanadyl
Sulfate
Liver Kidney (L)a Liver Kidney (L)a
0 8.05 ± 0.29 0.82 ± 0.03 7.51 ± 0.23 0.83 ± 0.01
125 9.50 ± 0.19**
(17.98)
0.80 ± 0.03
(−2.44)
10.12 ± 0.22**
(34.75)
0.90 ± 0.02
(8.43)
250  9.45 ± 0.44**
(17.41)
0.91 ± 0.02**
(10.98)
10.24 ± 0.28**
(36.35)
0.95 ± 0.03
(14.46)
500  8.42 ± 0.24**
(4.57)
0.82 ± 0.03
(0.00)
7.42 ± 0.21
(−1.20)
0.85 ± 0.02
(2.41)
1000  10.75 ± 0.45**
(43.14)
1.02 ± 0.03**
(22.89)
2000 6.46 ± 0.54**
(−13.98)
0.70 ± 0.04**
(−15.66)
Organ weights recorded at necropsy. Values represent group averages ± SEM,
n
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Table 5
Lung weights in (A) Harlan Sprague Dawley rats and (B) mice: sodium metavanadate
or  vanadyl sulfate.
(A)
mg/L Sodium Metavanadate Vanadyl Sulfate
♂ ♀ ♂ ♀
0 2.36 ± 0.36 1.33 ± 0.08 2.11 ± 0.18 1.37 ± 0.04
125 1.90 ± 0.13
(−19.49)
1.40 ± 0.06
(5.26)
1.75 ± 0.13
(−17.06)
1.25 ± 0.07
(−8.76)
250 1.33 ± 0.03**
(−43.64)
1.19 ± 0.03
(−10.53)
1.82 ± 0.32
(−13.74)
1.35 ± 0.1
(−1.46)
500 1.57 ± 0.12
(−33.47)
1.13 ± 0.07
(−15.04)
1.72 ± 0.18
(−18.48)
1.28 ± 0.06
(−6.57)
1000 1.37 ± 0.09*
(−35.07)
1.13 ± 0.05
(−17.52)
2000 1.15 ± 0.03
(−45.50)
0.86 ± 0.09
(−37.23)
(B)
mg/L Sodium Metavanadate Vanadyl Sulfate
♂ ♀ ♂ ♀
0 0.28 ± 0.02 0.23 ± 0.01 0.21 ± 0.02 0.16 ± 0.01
125 0.17 ± 0.01**
(−39.28)
0.16 ± 0.01**
(−30.43)
0.18 ± 0.01
(−14.29)
0.16 ± 0.01
(0.00)
250 0.18 ± 0.01**
(−35.71)
0.16 ± 0.01**
(−30.43)
0.17 ± 0.01
(−19.05)
0.16 ± 0.01
(0.00)
500 0.16 ± 0.01**
(−42.86)
0.14 ± 0.01**
(−39.13)
0.19 ±0.01
(−9.52)
0.16 ± 0.01
(0.00)
1000 0.18 ± 0.01
(−14.29)
0.14 ± 0.01
(−12.50)
2000 0.16 ± 0.01
(−23.81)
0.13 ± 0.00**
(−18.75)
Organ weights recorded at necropsy. Values represent group averages ± SEM, n = 4-
5.  Value in parenthesis is the percent different from controls.
* Indicates statistical signiﬁcance, p-value ≤ 0.05.
** Indicates statistical signiﬁcance, p-value ≤ 0.01.
Table 6
Thymus weights in Harlan Sprague Dawley rats and B6C3F1/N mice: vanadyl sulfate.
mg/L Rats Mice
♂ ♀ ♂ ♀
0 0.57 ± 0.05 0.45 ± 0.01 0.05 ± 0.00 0.08 ± 0.00
125 0.61 ± 0.02
(7.02)
0.42 ± 0.03
(−6.67)
0.05 ± 0.00
(0.00)
0.08 ± 0.00
(0.32)
250  0.54 ± 0.03
(−5.26)
0.45 ± 0.02
(0.00)
0.05 ± 0.00
(0.00)
0.07 ± 0.00
(−12.5)
500 0.49 ± 0.02
(−14.04)
0.41 ± 0.03
(−8.89)
0.05 ± 0.00
(0.00)
0.08 ± 0.00
(0.00)
1000 0.52 ± 0.04
(−8.77)
0.47 ± 0.02
(4.44)
0.06 ± 0.01
(20.00)
0.06 ± 0.01
(−25.00)
2000 0.36 ± 0.04
(−36.84)
0.25 ± 0.09
(−44.44)
0.02 ± 0.00**
(−60.00)
0.02 ± 0.00**
(−75.00) = 4–5. Value in parenthesis is the percent different from controls.
a Organ weights shown are for the left (L) kidney.
** Indicates statistical signiﬁcance, p-value ≤ 0.01.
000 mg/L groups (Fig. 1). Lower water consumption likely con-
ributed to body weight effects seen in the 2000 mg/L exposure
roups. Rats exposed to vanadyl sulfate had signiﬁcantly lower
ody weights at study termination in the 2000 mg/L group only
Fig. 1B, D), while mice exposed to vanadyl sulfate had lower body
eights in the 1000 and 2000 mg/L groups at termination (Fig. 1F,
).
Despite similarities in water/compound consumption between
nimals exposed to vanadyl sulfate or sodium metavanadate,
odium metavanadate-exposed animals experienced effects on
ody weight at lower doses, down to 250 mg/L for male rats
Fig. 1A). Body weight effects observed early for female rats were
esolved at study termination in surviving groups (Fig. 1C). Male
nd female mice had body weight effects in the 500 mg/L group at
tudy termination and in the 1000 and 2000 mg/L groups prior to
arly removal (Fig. 1E, G).
.4. Organ weights
Signiﬁcant organ weight changes were observed in several tis-
ues, however most changes were likely related to body weight
ffects. Organ weights for sodium metavanadate are only avail-
ble for the groups that were euthanized at study termination
day 15): 0, 125, 250 and 500 mg/L. Male rats, only, had signiﬁ-
antly higher liver weights following exposure to both compounds
Table 4). The dose response following exposure to vanadyl sulfate
as not strong, showing higher weights, compared to controls, at
25, 250 and 1000 mg/L but not at 500 mg/L; body weight effects
t 2000 mg/L resulted in a lower liver weight compared to con-
rols. Male rats exposed to sodium metavanadate had higher liver
eights at 125 and 250 mg/L, however not at 500 mg/L, despite
ody weights being within 10% of controls.
Kidney weights followed a similar trend as liver weights in male
ats exposed to vanadyl sulfate (Table 4); higher kidney weights
ere seen at 1000 mg/L, while body weight effects resulted in lower
idney weights at 2000 mg/L. Increased kidney weights were only
bserved in male rats exposed to 250 mg/L sodium metavanadate
ith no signiﬁcant difference observed in the 500 mg/L exposure
roup. Increased liver or kidney weights were not observed in any
ther sex/species exposed to either compound.
Lung weights in male and female mice exposed to sodium meta-
anadate were signiﬁcantly lower than controls in all exposed
roups in the absence of body weight effects, ranging from −30
o −40% compared to controls (Table 5B). Lower lung weights, that
id not reach signiﬁcance, were also observed in other groups in theOrgan weights recorded at necropsy. Values represent group averages ± SEM,
n  = 4–5. Value in parenthesis is the percent different from controls.
** Indicates statistical signiﬁcance, p-value ≤ 0.01.
absence of body weight effects, e.g. male rats exposed to vanadyl
sulfate or sodium metavanadate (Table 5A). Effects on the thymus
were observed in all animals exposed to vanadyl sulfate, usually in
the presence of smaller magnitude body weight effects and likely
stress related (Table 6). Mice exposed to sodium metavanadate
also had lower thymus weights (males: −50.0%, females: −28.6%
at 500 mg/L) in the presence of smaller magnitude body weight
effects (data not shown).4. Discussion
The NTP has compared the short-term toxicity of vanadyl sul-
fate (VIV) and sodium metavanadate (VV) in HSD rats and B6C3F1/N
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ice following exposure via drinking water. Vanadium com-
ounds, of various oxidation states, are of human health concern
ollowing oral exposure and are of interest to the U.S. Environmen-
al Protection Agency for potential regulation in drinking water
29].
Under the condition of these studies, it appears that sodium
etavanadate was more toxic than vanadyl sulfate. While drink-
ng water exposure to vanadyl sulfate or sodium metavanadate
or 14 days resulted in similar levels of vanadium exposure
mg/kg/day) (Table 3), animals exposed to vanadate exhibited
ortality/moribunidty and clinical signs of toxicity, e.g. lethargy,
bnormal gait and breathing, which were not observed in vanadyl-
xposed animals. The NTP has previously studied chromium
ompounds of different oxidation states and observed that the
ore oxidized form, a hexavalent compound, sodium dichromate
ihydrate, was more toxic than the trivalent species, chromium
icolinate monohydrate [17,18,26,27].
One confounding variable in the interpretation of data in the
resent study is the reduced water consumption and potential
ehydration of the animals. While some clinical observations noted
re consistent with dehydration, the studies were not designed to
irectly assess dehydration. Further, it is unlikely that all observed
ffects were caused by dehydration. Lower water consumption was
bserved for all compounds, sexes and species; however, mortal-
ty and selected clinical observations were only noted in sodium
etavanadate animals. For the 1000 and 2000 mg/L sodium meta-
anadate groups, it is possible that lower water consumption,
ombined with higher toxicity versus vanadyl sulfate, contributed
o these effects. While the present studies indicate a difference in
oxicity between vanadyl sulfate (VIV) and sodium metavanadate
VV), further studies are needed to gain a better understanding of
otential differences in disposition and toxicity.
Higher organ weights observed in the present study may  indi-
ate that the liver and kidney are potential target organs following
ral exposure to soluble vanadium compounds. Weight change in
he liver of male rats was observed at the lowest exposure con-
entration for both compounds; however this weight change was
ot observed in any other sex/species. Studies in the literature
uggest that vanadyl sulfate and sodium metavanadate may  have
ffects on metabolic pathways, however no histopathological evi-
ence of toxicity was observed in multiple studies with exposures
p to one year at comparable doses to those used in the present
tudies [1,31,6]. Kidney weight changes were less consistent than
iver changes in the male rats, however these changes may  indi-
ate potential toxicity. The literature available for kidney effects
s variable; histopathologic changes have been reported in the
idney of rats exposed to sodium metavanadate for 3 months at
.5 mg  V/kg/day, while another study exposing at 19 mg  V/kg/day
or one year reported no histopathological lesions [31,6].
Lower lung weights observed in the present study were fairly
onsistent between compounds and for most sex/species. These
hanges were, in most cases, in the absence of body weight effects.
ata in the literature regarding the effect of vanadium exposure
n the lung are limited to weight increases following inhalation
xposure, e.g. [16]. Lower lung weight that is not associated with
ower body weight is a novel ﬁnding with unknown toxicologi-
al relevance and will be considered further in subsequent, more
omprehensive evaluations of vanadium toxicity following oral
xposure.
Several studies in the literature, have reported effects of vana-
ium on developmental and reproductive endpoints following oral
xposure [7,10,11,21]. In particular, decreased reproductive per-
ormance of male rats and mice (mated with naïve females), was
eported following oral exposure to vanadyl sulfate or sodium
etavanadate, respectively, for 8–9 weeks [10,11]. Weight changes
n male reproductive-associated organs were not observed ineports 3 (2016) 531–538 537
the current studies, however more comprehensive assessment of
effects on spermatogenesis would be needed to conﬁrm whether
or not vanadium has an impact on male reproductive performance.
The present studies will be used to select doses for subchronic
toxicity evaluations of tetra- and pentavalent vanadium com-
pounds in order to ﬁll critical data gaps in the literature and help
understand differences in toxicity between soluble vanadium with
different oxidation states. Inter-conversion of oxidation state, in
vivo, may  complicate the interpretation of differences in toxicity, in
these and future studies of vanadyl and vanadate compounds. The
gastrointestinal (GI) environment has a wide range of pHs, result-
ing in ingested material experiencing both reduction and oxidation
in different compartments of the GI tract following consumption.
Oxidation, or more likely reduction reactions in the stomach, must
also compete with gastric emptying to determine what species are
present within lower sections of the GI tract. As a result, it is difﬁ-
cult to identify the oxidation state(s) of vanadium that are absorbed
by the GI tract and distributed to tissues. In the NTP studies of hex-
avalent and trivalent chromium, oxidation state within tissues was
not determined, however, tissue burden data of total chromium
suggested that overall absorption of the hexavalent species was
higher than the trivalent, helping to explain differences observed
in toxicity [4]. Therefore, some understanding of total body burden
may  be used as a surrogate for determination of oxidation state in
tissues and can help explain differences in toxicity. Studies in the
literature have assessed the oral bioavailability of various vana-
dium compounds in tissues and urine, under different conditions,
and reported a wide range of values from less than 1%, up to 16%
[1,3,23]. By testing tetravalent and pentavalent vanadium under
nearly identical conditions, the present and future NTP studies can
begin to explore similarities or differences in biological response
between the different oxidation states. As the NTP moves forward
with subchronic evaluations of vanadyl sulfate and sodium meta-
vanadate, it will be important to be aware of the potential for in vivo
oxidation/reduction and to use available tools to assist in the expla-
nation of differences in toxicity.
5. Conclusions
Drinking water exposure (0, 125, 250, 500, 1000, 2000 mg/L) of
HSD rats and B6C3F1/N mice to vanadyl sulfate or sodium meta-
vanadate (0, 125, 250, 500, 1000 or 2000 mg/L) resulted in lower
water consumption at most doses with accompanying decreases in
body weight at the highest exposure concentrations. Clinical obser-
vations and toxicity observed suggest that sodium metavanadate
is more toxic than vanadyl sulfate. Despite having similar con-
sumption of compound and total vanadium between vanadyl and
vanadate-exposed animals, rats and mice in vanadate exposure
groups exhibited lethargy, abnormal gait and abnormal breath-
ing that were not observed in animals following vanadyl sulfate
exposure. Based on these studies, the NTP has designed subchronic
drinking water studies of vanadyl sulfate and sodium metavana-
date in HSD rats, following perinatal exposure, and B6C3F1/N
mice at concentrations of 0, 31.3, 62.5, 125, 250 or 500 mg/L
for a more comprehensive comparison and assessment of toxi-
cological characterization. These studies will include an extensive
histopathological evaluation in rats and mice, as well as additional
assessments in rats, including developmental landmarks, absorp-
tion/excretion and red cell/plasma partitioning of vanadium.Transparency document
The http://dx.doi.org/10.1016/j.toxrep.2016.05.001 associated
with this article can be found in the online version.
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